痛风控制患者与医生评估的预测因素
研究纳入223例每日服用别嘌醇≥300 mg的痛风患者,在标准化评估访视中由患者和医生用0–10分量表评估痛风控制。患者平均评分8.09±2.24高于医生的7.38±2.63(P<0.001);近12个月及近3个月无痛风发作和血尿酸达标(<6 mg/dl)与两者更高评分相关,无痛风石仅预测医生更高评分;22.3%评分不一致,近3个月痛风发作(OR 5.9,P<0.001)和痛风石(OR 3.1,P=0.007)预测医生评分低于患者。
要点
- 患者痛风控制评分均值8.09±2.24,医生7.38±2.63,比较P<0.001。
- 近12个月及近3个月无痛风发作、血尿酸<6 mg/dl与患者和医生更高评分相关。
- 22.3%评分不一致,近3个月痛风发作(OR 5.9)和痛风石(OR 3.1)预测医生评分低于患者。
核心结论
- 对患者和医生而言,无痛风发作和血尿酸达治疗目标均预测痛风控制评估更高,但两者评估不一致并不少见,近期痛风发作和痛风石预测医生评分低于患者。
研究设计与样本
- 223例每日服用别嘌醇≥300 mg的痛风患者参加标准化痛风评估访视,患者和医生用数字评定量表(0=完全未控制,10=完全控制)评估当前痛风控制。
- 患者与医生评分绝对差>2分定义为评估不一致。
主要发现
- 患者痛风控制评分均值±标准差为8.09±2.24,医生为7.38±2.63(比较P<0.001)。
- 近12个月和近3个月无痛风发作及血尿酸达治疗目标(<6 mg/dl)与患者和医生更高痛风控制评分相关。
- 无痛风石也预测医生更高痛风控制评分,但不预测患者更高评分。
- 50例参与者(22.3%)存在痛风控制评分不一致,多数因医生对疾病控制评估较低。
- 近3个月痛风发作(OR 5.9,P<0.001)和痛风石(OR 3.1,P=0.007)预测医生评分低于患者的不一致评估。
关键数值与推荐
- 患者痛风控制评分均值±标准差8.09±2.24,医生7.38±2.63(比较P<0.001)。
- 血尿酸治疗目标为<6 mg/dl。
- 评分不一致定义为患者与医生评分绝对差>2分。
- 近3个月痛风发作OR 5.9(P<0.001)、痛风石OR 3.1(P=0.007)预测医生评分低于患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand the clinical variables that contribute to the patient and physician assessments of gout control and which variables predict discordant assessments. METHODS: Patients (n = 223) with gout taking allopurinol ≥300 mg daily attended a standardized gout assessment visit. Participants and physicians completed questionnaires rating their assessment of current gout control using a numerical rating scale (0 = not at all controlled, 10 = fully controlled). Discordance between patients' and physicians' scores was defined as an absolute difference of >2 units. RESULTS: The mean ± SD patient gout control score was 8.09 ± 2.24, and the physician gout control score was 7.38 ± 2.63 (P < 0.001 for comparison). Absence of gout flares in the last 12 months and in the last 3 months and serum urate at the treatment target (<6 mg/dl) were associated with higher patient and physician gout control scores. Absence of tophus also predicted higher physician, but not patient, gout control scores. Discordant scores for gout control were present in 50 participants (22.3%), mostly due to lower assessment of disease control by physicians. Gout flare in the preceding 3 months (odds ratio [OR] 5.9, P < 0.001) and tophus (OR 3.1, P = 0.007) predicted discordant disease-control assessments in which physicians scored lower gout control than patients. CONCLUSION: For both patients and physicians, absence of gout flares and serum urate levels at the treatment target predict assessment of gout control. However, discordance between patients and physicians in their assessment of disease control is not uncommon, with recent gout flares and tophus predicting lower scores by physicians than patients.
引用
- Dalbeth N, Frampton C, Fung M, et al. Predictors of Patient and Physician Assessments of Gout Control. Arthritis Care Res (Hoboken). 2022. PMID: 36263859. doi:10.1002/acr.25046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。